This week we highlight a slow start to the year for life sciences initial public offerings, Medicare’s decision on Alzheimer’s disease reimbursement, the use of machine learning and artificial intelligence in clinical trials and the rapidly growing market for virtual trials. Finally, we look at how the ... READ MORE >
IPO
Macroeconomic drivers for life sciences: Spring 2022 outlook
The three areas that middle market life sciences companies should pay specific attention to are supply chains, labor and capital markets. We anticipate a decreased appetite from private investors to pay high company valuations, but an uptick in the number of life sciences startups. This presents an ... READ MORE >
5 things to know in life sciences: Week of August 2
This week we start with a look at the potential for gene and cell therapy to radically change health care over the coming decade. Although there are few approved drugs using these technologies today, the pipeline of candidates in all phases of clinical studies is full of potential cell and gene therapy ... READ MORE >
5 things to know in life sciences: Week of July 26
This week we highlight the United States Food and Drug Administration’s approval of an insulin biosimilar and their granting of its status as interchangeable with the name brand drug. This promises significant savings for diabetic patients who often face financial hardships because of the cost of care. We ... READ MORE >
SPAC IPO market pauses as investors and regulators reevaluate
Initial public offerings of special purpose acquisition companies (SPACs) have almost ground to a halt, a rapid and spectacular reversal of one of the hottest trends in 2020 and the first quarter of 2021. SPACs’ share price performance—as reflected by the Defiance Next Gen SPAC Derived Exchange-Traded ... READ MORE >
CHART OF THE DAY: December is anticipated to be the biggest on record for IPOs
Special purpose acquisition companies have been hot this year, but the traditional initial public offering is closing out the year even stronger. Performance of traditional IPOs has outpaced SPACs throughout the fourth quarter, and this month is anticipated to be the biggest December on record for IPOs, ... READ MORE >
Once derided, special purpose acquisition companies go mainstream amid turbulent markets
It wasn’t too long ago that there was an order to the universe when companies wanted to go public, and the traditional initial public offering was at the top of the list. Ranking near the bottom – the province of often-questionable listings – was an investment vehicle called the special purpose ... READ MORE >